Remohab is a medical device startup from Osaka University, working on the development of a remote cardiac rehabilitation system. As the first company in the Japan Bio design Program, its participation in Air Water Group is the first M&A exit case in Japan in the DTx (Digital Therapeutics) field. In 2024, its completed Japan’s first physician-initiated Phase III clinical trial for a remote cardiac rehabilitation system, and on June 23, 2025, its product “Remohab CR U” received approval from the Pharmaceuticals and Medical Devices Agency (PMDA). Remohab aims to launch the product in Japan first and promote its nationwide adoption with future global expansion in mind.
[画像: https://prtimes.jp/i/36290/15/resize/d36290-15-4105ebe19f0f06b20dbe-0.jpg ] https://www.kenko810.com/健康ハートの日8月10日が810（ハート）と読めることから、1985年にこの日を「健康ハートの日」...
株式会社リモハブ（本社：大阪府大阪市 代表取締役社長：谷口 達典 以下、当社）は、遠隔心臓リハビリテーション（以下、遠隔心臓リハビリ）の実施を支援する医療機器プログラム「リモハブ CR U」の製造販売...
[画像: https://prtimes.jp/i/36290/11/resize/d36290-11-e578c6a1d8f4b5c611e4-0.jpg ] 株式会社リモハブは、健康ハートの日 (kenko810.com)に協賛しています 7月から9月は健康ハートの強化月間！楽しく学べる...
[画像1: https://prtimes.jp/i/36290/10/resize/d36290-10-101749-2.png ] ●治験実施に至った背景 日本における年間総死亡数のうち19万6,113人の原因が心疾患であり（死因別死亡数全体の第２位15.2％）、...
【リモハブについて】 スタンフォード大学発の医療機器開発アントレプレナー育成プログラム「ジャパンバイオデザイン」のフェローシップ 第１期メンバーである循環器内科専門医の谷口が2017年に設立した大阪大...
【資金調達の目的と使途】 今回の増資は、弊社が開発する遠隔心臓リハビリテーションを用いた多施設大規模治験費用に充当することを目的としたものです。本資金により、今春から開始する治験準備や新医療機器と...
      【本共同研究について】 本臨床試験では、通常の診療と同様に通院して実施する心臓リハビリテーション通院と在宅運動療法を指導します。その在宅運動療法の一部を、遠隔心臓リハ...
  [画像1: https://prtimes.jp/i/36290/2/resize/d36290-2-428454-0.jpg ] （発表者 左から順に） 金沢 崇 (Hack Ventures株式会社 マネージング・パートナー) 神保 敏明（大阪大学ベンチャ...
We are an Osaka University spin-out drug discovery startup, co-developing a novel cancer immunotherapy with Osaka University. Our proprietary platform, HVJ-E/IM-0101, converts neutrophils into the anti-tumor N1 phenotype and, through local administration, remodels the systemic tumor microenvironment (TME) toward an anti-tumor state. This enables activation of neutrophils—the most abundant immune cell type—previously difficult to harness with existing approaches. Building on accumulated clinical safety data of IM-0101 and tumor immune amplification via CXCL2 gene delivery, we plan to expand to IM-0102 for lung cancer over the next few years.
Drug development for neurodegenerative diseases.
We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.
Solaris Bio revolutionizes regenerative medicine by integrating proprietary Animal-Origin-Free (AOF) formulation designs with advanced cell protection expertise. Centered on our "Organic Solvent-Free Cryopreservation Solution," which boasts the highest safety standards, we offer comprehensive cell manufacturing solutions, including world-class growth media. Leveraging innovative R&D and quality verified by the Certificate of Material Eligibility, we simultaneously enhance cell product efficacy and reduce costs, powerfully accelerating the social implementation of next-generation healthcare.